Skip to content

SPRING PHARMACEUTICAL GROUP, INC.: 10-Q filed 2012-11-14

What SPRING PHARMACEUTICAL GROUP, INC. reported in its quarterly report filed 2012-11-14 (fiscal Q2 2012): 31 published measures, 85 facts as tagged in accession 0001144204-12-062227.

This filing

Form
10-Q (quarterly report)
Filed
2012-11-14
Fiscal period
fiscal Q2 2012
Accession
0001144204-12-062227 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All SPRING PHARMACEUTICAL GROUP, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-09-3056,072,335USD
At 2012-03-3153,008,384USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-09-306,123,180USD
At 2012-03-3111,317,387USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-09-3049,949,155USD
At 2012-06-3043,907,829USD
At 2012-03-3141,690,997USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-09-3024,569,564USD
At 2012-03-3122,146,240USD
At 2012-02-2922,146,240USD
At 2011-09-3019,697,004USD
At 2011-06-3016,316,460USD
At 2011-03-316,046,804USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-306,170,105USD92
2012-04-01 to 2012-09-308,422,815USD183
2012-04-01 to 2012-06-302,252,710USD91
2011-07-01 to 2011-09-302,277,026USD92
2011-04-01 to 2011-09-303,513,178USD183

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-04-01 to 2012-09-302,366,236USD183
2011-04-01 to 2011-09-303,212,592USD183

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-04-01 to 2012-09-302,695USD183
2011-04-01 to 2011-09-300USD183

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-04-01 to 2012-09-30-2,695USD183
2011-04-01 to 2011-09-309,948,966USD183

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2012-07-01 to 2012-09-3031,610,679shares92
2011-07-01 to 2011-09-3031,610,679shares92

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2012-07-01 to 2012-09-30583,197USD92
2012-04-01 to 2012-09-301,326,424USD183
2011-07-01 to 2011-09-30759,009USD92
2011-04-01 to 2011-09-301,171,060USD183

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-09-309,411,982USD
At 2012-03-319,663,338USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-04-01 to 2012-09-305,000USD183
2011-04-01 to 2011-09-300USD183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-07-01 to 2012-09-302,302,028USD92
2012-04-01 to 2012-09-305,264,933USD183
2011-07-01 to 2011-09-302,960,074USD92
2011-04-01 to 2011-09-304,540,103USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-09-3028,351,902USD
At 2012-03-3124,261,553USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-09-305,016,802USD
At 2012-03-315,785,495USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2012-09-300USD
At 2012-03-31115,938USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-07-01 to 2012-09-301,830,769USD92
2012-04-01 to 2012-09-303,415,922USD183
2011-07-01 to 2011-09-301,861,709USD92
2011-04-01 to 2011-09-304,643,599USD183

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2012-09-303,761,605USD
At 2012-03-311,978,488USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2012-07-01 to 2012-09-304,132,797USD92
2012-04-01 to 2012-09-308,680,855USD183
2011-07-01 to 2011-09-304,821,783USD92
2011-04-01 to 2011-09-309,183,702USD183

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-07-01 to 2012-09-30326,135USD92
2012-04-01 to 2012-09-30548,700USD183
2011-07-01 to 2011-09-30200,303USD92
2011-04-01 to 2011-09-30393,821USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-09-3073,780,610shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-09-3036,884,593USD
At 2012-03-3136,879,643USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2012-09-303,171,499USD
At 2012-03-313,341,156USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2012-09-3010,737,530USD
At 2012-03-3110,812,557USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2012-09-301,325,548USD
At 2012-03-311,149,219USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2012-09-3018,090,089USD
At 2012-03-3118,863,510USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2012-07-01 to 2012-09-306,046,326USD92
2012-04-01 to 2012-09-308,253,158USD183
2011-07-01 to 2011-09-302,720,511USD92
2011-04-01 to 2011-09-304,362,827USD183

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-30710,515USD92
2012-04-01 to 2012-09-301,202,898USD183
2011-07-01 to 2011-09-301,049,403USD92
2011-04-01 to 2011-09-302,458,223USD183

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2012-07-01 to 2012-09-30176,330USD92
2012-04-01 to 2012-09-30264,327USD183
2011-07-01 to 2011-09-3027,549USD92
2011-04-01 to 2011-09-30155,203USD183

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2012-04-01 to 2012-09-30115,938USD183
2011-04-01 to 2011-09-300USD183

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2012-04-01 to 2012-09-30-1,783,117USD183
2011-04-01 to 2011-09-30-1,745,214USD183

Inspect the source

Entity
SPRING PHARMACEUTICAL GROUP, INC. / CIK 0000847464
Captured
SEC response SHA-256
21fd63bfa4a441f5dd22dbcc8093e88a40c5d63950c8b6833c77a7b4245f4dc7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000847464.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))